[ protective effect of FXIII Val34Leu polymorphism against deep vein thrombosis: a report from Iranian Blood Transfusion Organization [IBTO]]

The coagulation factor XIII is a pro-transglutaminase enzyme with tetrameric structure. An exchange of G for A in exon 2 of A subunit results in replacement of valine with leucine in amino acid 34. As a result of this substitution mutation, the clots produced are fragile and loose therefore it seems that FXIII Val34Leu polymorphism acts as a factor for individual protection against thrombosis Objectives: To determine the prevalence and role of FXIIIA Val34Leu polymorphism against deep vein thrombosis. This was a retrospective case-control study performed on 116 patients with DVT who were referred to Thrombosis and Homeostasis Laboratory affiliated to Iranian Blood Transfusion Organization. Also, 100 healthy individuals [blood donors] were recruited as control. Following DNA extraction and application of PCR and RFLP techniques in presence of restriction enzyme Cfo1, the genotypes of FXIII Val34Leu polymorphism were identified. The data were analyzed using chi square test as well as calculation of OD ratio and 95% confidence interval. The prevalence of FXIII Val34Leu polymorphism among the case and control groups was 22.4% and 37.4%, respectively. While the allele frequency of leucine in case group was 14.7% it was 20.2% in control group. No significant correlation between polymorphism and sex was established. According to our data, no association between the FXIII Val34Leu polymorphism and protection against deep vein thrombosis was demonstrated. Therefore, it seems that this polymorphism occurs as a natural phenomenon and unaffected by gender

[Investigation quality of self care in patients members of families which have simplex and multiplex hepatitis B]

Family history of one member suffering from hepatitis B of family is one of the most important ways of illness transmission in Iran. Thus attention to quality of self care of patients of hepatitis B family has vital role in prevention and control in family and society. This research is descriptive study. Samples of this research included 250 patients which 160 persons belonged to simplex hepatitis B families and 90 persons belonged to multiplex hepatitis B families. Patients refer to the center of blood transfusion organization from all of area of Gillan province. In this study data has collected by patens' questionnaire include: demographic qualifications that were designed in two parts 1- individual qualifications and illness qualifications and questions were about quality self care of drug regimen meal regimen, addictions, precautions standard, follow up disease and diagnostic quality self care in these groups has been analyzed in SPSS statistical soft ware by statistical tests such as chi2 test and fisher test. [p<0.005]. Our results show that [64%] patients of simplex family and [85.6%] patients of family multiplex have not suitable quality self care. In response to hypothesises [there is relationship between quality of self care of patients members in family and increasing of HBSAg cases] findings show that exists meaningful relation between self care about hepatitis B and increasing cases HBSAg in families [p<0.05]. Regarding to dimensions of quality selfcare about hepatitis B disease has important role in preventing from increasing cases HBSAg in families. Particularly regarding to results of research which indicate unsuitable quality self care of patients about drug regime "diet or therapy" "addictions" follow up disease. Therefore in order to control the hepatitis B in family according to the results of this study it is suggested further efforts should be down. The results of this study can be used for other patients infectious such as hepatitis c and Aids

preliminary study on the effect of two therapeutic procedures on the expression of BCR-ABL gene in CML patients

Chronic myelogensis leukemia [CML] is a chronic myeloproliferative disorder resulting from a specific mutation in a pluripotent stem cell. The association of Philadelphia chromosome with this disorder was described in 1973. Subsequently, the BCR-ABL fusion gene and its product which is a tyrosin kinase inhibiting apoptosis were introduced. The treatment of choice for these patients is BMT as well as the new molecular treatment of imatinib mesylate. The present study was designed in order to compare the rate of expression of the BCR-ABL gene in patients who had undergone treatment by bone marrow transplantation with those treated by imatimib. Expression of BCR-ABL gene was measured in 34 patients 17 patients were treated with BMT and 17 with imatinib mesylate using quantitative PCR on a light cycler instrument. The results obtained in this preliminary study demonstrates that rate of gene expression patients treated with imatinib mesylate for more than 8 month was similar to that found in patients treated with 8 BMT who were in relatively stable conditions. This finding may be an indication that imatinib mesylate as a molecular inhibitor can have the same effect as BMT but with less adverse effects. Clearly definite conclusions require more extensive studies on larger number of patients